Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
Carroll
Peter R
PR
Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA. Pcarroll@urol.ucsf.edu
Kantoff
Philip W
PW
Balk
Steven P
SP
Brown
Myles A
MA
D'amico
Anthony V
AV
George
Daniel J
DJ
Grossfeld
Gary D
GD
Johnson
Candace S
CS
Kelly
William Kevin
WK
Klotz
Laurence
L
Lee
W Robert
WR
Lubeck
Deborah P
DP
Mcleod
David G
DG
Oh
William K
WK
Pollack
Alan
A
Sartor
Oliver
O
Smith
Matthew R
MR
Hart
Carol
C
D000726:Androgen Antagonists / Q000627:therapeutic use*; D001918:Brachytherapy; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D020249:Hormone Replacement Therapy / Q000592:standards; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011788:Quality of Life
D000726:Androgen Antagonists; D004791:Enzyme Inhibitors; D007987:Gonadotropin-Releasing Hormone; D011505:Protein-Tyrosine Kinases